Macrogen, Inc. (KOSDAQ:038290)
11,000
+100 (0.92%)
Nov 2, 2026, 3:30 PM KST
Macrogen Revenue
Macrogen had revenue of 51.00B KRW in the quarter ending June 30, 2026, with 4.12% growth. This brings the company's total for the last twelve months to 201.62B, up 23.00% year-over-year. In the year 2025, Macrogen had annual revenue of 195.27B with 43.82% growth. That makes Macrogen the 19,622nd largest company in the world by revenue and 1,031st in South Korea.
Revenue (ttm)
201.62B
Revenue Growth
+23.00%
P/S Ratio
0.59
Revenue / Employee
426.25M
Employees
473
Market Cap
119.26B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Macrogen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 195.27B | 59.49B | 43.82% |
| Dec 31, 2024 | 135.78B | 2.97B | 2.24% |
| Dec 31, 2023 | 132.80B | -5.81B | -4.19% |
| Dec 31, 2022 | 138.62B | 9.44B | 7.31% |
| Dec 31, 2021 | 129.17B | 16.57B | 14.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| HANDOK | 560.89B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Kyongbo Pharmaceutical | 279.55B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| ALTEOGEN | 254.01B |